Anti-LAG-3 Monoclonal Antibody HLX26 clinical trials
Also written HLX26.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Anti-LAG-3 Monoclonal Antibody HLX26 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Anti-LAG-3 Monoclonal Antibody HLX26 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsActive, not recruitingPhase 2Shanghai Henlius BiotechNCT05787613Written as HLX26
- Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRCTerminatedPhase 2Shanghai Henlius BiotechNCT05584137Written as HLX26
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or LymphomaCompletedPhase 1Shanghai Henlius BiotechNCT05078593Written as HLX26
- Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid TumorCompletedPhase 1Shanghai Henlius BiotechNCT05400265Written as HLX26